Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States

Published:2024-06-06 Issue:1 Volume:27 Page:766-776
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Matasar Matthew¹,Sanchez Alvarez Javier²,Parisé Hélène³^ORCID,Zuk Eric³^ORCID,Di Maio Danilo²^ORCID,Shapouri Sheila⁴^ORCID,Kim Eunice⁴,Lin Shih-Wen⁴^ORCID

Affiliation:

1. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

2. F. Hoffmann-La Roche, Basel, Switzerland

3. Medicus Economics LLC, Boston, MA, USA

4. Genentech, Inc., South San Francisco, CA, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2352820

Reference51 articles.

1. National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ)–health professional version. [cited 2022 Dec 6]. Available from: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq.

2. Follicular lymphoma: 2020 update on diagnosis and management

3. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

4. Burden of illness of follicular lymphoma and marginal zone lymphoma

5. U.S. Food and Drug Administration. FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma. [cited 2022 Dec 22]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mosunetuzumab for the treatment of follicular lymphoma;Expert Opinion on Biological Therapy;2024-09-11